CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study

Aglaia Schiza; Elena Fountzilas; Laura Biganzoli; Evangelos Digkas; Kamilla Fjermeros; Jürgen Geisler; Peeter Karihtala; Henrik Lindman; Icro Meattini; Montserrat Munoz-Mateu; Emanuela Risi; Nikolaos Spathas; Meri Utriainen; Luca Visani; Antonis Valachis; Mukhrizah Othman

doi:10.1016/j.jgo.2026.103068

CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study

Aglaia Schiza
, Elena Fountzilas
, Laura Biganzoli
, Evangelos Digkas
, Kamilla Fjermeros
, Jürgen Geisler
, Peeter Karihtala
, Henrik Lindman
, Icro Meattini
, Montserrat Munoz-Mateu
, Emanuela Risi
, Nikolaos Spathas
, Meri Utriainen
, Luca Visani
, Antonis Valachis
, Mukhrizah Othman

Forskningsoutput: Tidskriftsbidrag › Brev › Vetenskaplig › Peer review

Sammanfattning

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) improve outcomes in HR+/HER2− metastatic breast cancer (MBC) [1–5]. However, older adults remain underrepresented in pivotal trials [6]. Although available evidence indicates that older patients benefit from CDK4/6i, higher toxicity and treatment discontinuation rates have been documented [7,8]. Guidelines do not recommend age- or frailty-based initial dose adjustments, leaving oncologists to individualize treatment without prospective evidence.

Originalspråk	engelska
Artikelnummer	103068
Tidskrift	Journal of geriatric oncology
Volym	17
Nummer	7
Antal sidor	4
ISSN	1879-4068
DOI	https://doi.org/10.1016/j.jgo.2026.103068
Status	Publicerad - sep. 2026
MoE-publikationstyp	A1 Tidskriftsartikel-refererad

Vetenskapsgrenar

3122 Cancersjukdomar

Åtkomst av dokument

10.1016/j.jgo.2026.103068Licens: CC BY

CDK4_6 inhibitor dose patterns among older patients with metastatic breast cancer_ A multinational survey studySlutlig publicerad version, 736 KBLicens: CC BY

Citera det här

Schiza, A., Fountzilas, E., Biganzoli, L., Digkas, E., Fjermeros, K., Geisler, J., Karihtala, P., Lindman, H., Meattini, I., Munoz-Mateu, M., Risi, E., Spathas, N., Utriainen, M., Visani, L., Valachis, A., & Othman, M. (2026). CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study. Journal of geriatric oncology, 17(7), Artikel 103068. https://doi.org/10.1016/j.jgo.2026.103068

@article{a2147dd5869242cd83b6e6e910b51ac7,

title = "CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study",

abstract = "Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) improve outcomes in HR+/HER2− metastatic breast cancer (MBC) [1–5]. However, older adults remain underrepresented in pivotal trials [6]. Although available evidence indicates that older patients benefit from CDK4/6i, higher toxicity and treatment discontinuation rates have been documented [7,8]. Guidelines do not recommend age- or frailty-based initial dose adjustments, leaving oncologists to individualize treatment without prospective evidence.",

keywords = "CDK4/6 inhibitors, Dose reduction, Geriatric oncology, Metastatic breast cancer, Multinational survey, Prescribing practices, 3122 Cancers",

author = "Aglaia Schiza and Elena Fountzilas and Laura Biganzoli and Evangelos Digkas and Kamilla Fjermeros and J{\"u}rgen Geisler and Peeter Karihtala and Henrik Lindman and Icro Meattini and Montserrat Munoz-Mateu and Emanuela Risi and Nikolaos Spathas and Meri Utriainen and Luca Visani and Antonis Valachis and Mukhrizah Othman",

year = "2026",

month = sep,

doi = "10.1016/j.jgo.2026.103068",

language = "English",

volume = "17",

journal = "Journal of geriatric oncology",

issn = "1879-4068",

publisher = "Elsevier Ltd. ",

number = "7",

}

Schiza, A, Fountzilas, E, Biganzoli, L, Digkas, E, Fjermeros, K, Geisler, J, Karihtala, P, Lindman, H, Meattini, I, Munoz-Mateu, M, Risi, E, Spathas, N, Utriainen, M, Visani, L, Valachis, A & Othman, M 2026, 'CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer: A multinational survey study', Journal of geriatric oncology, vol. 17, nr. 7, 103068. https://doi.org/10.1016/j.jgo.2026.103068

TY - JOUR

T1 - CDK4/6 inhibitor dose patterns among older patients with metastatic breast cancer

T2 - A multinational survey study

AU - Schiza, Aglaia

AU - Fountzilas, Elena

AU - Biganzoli, Laura

AU - Digkas, Evangelos

AU - Fjermeros, Kamilla

AU - Geisler, Jürgen

AU - Karihtala, Peeter

AU - Lindman, Henrik

AU - Meattini, Icro

AU - Munoz-Mateu, Montserrat

AU - Risi, Emanuela

AU - Spathas, Nikolaos

AU - Utriainen, Meri

AU - Visani, Luca

AU - Valachis, Antonis

AU - Othman, Mukhrizah

PY - 2026/9

Y1 - 2026/9

N2 - Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) improve outcomes in HR+/HER2− metastatic breast cancer (MBC) [1–5]. However, older adults remain underrepresented in pivotal trials [6]. Although available evidence indicates that older patients benefit from CDK4/6i, higher toxicity and treatment discontinuation rates have been documented [7,8]. Guidelines do not recommend age- or frailty-based initial dose adjustments, leaving oncologists to individualize treatment without prospective evidence.

AB - Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) improve outcomes in HR+/HER2− metastatic breast cancer (MBC) [1–5]. However, older adults remain underrepresented in pivotal trials [6]. Although available evidence indicates that older patients benefit from CDK4/6i, higher toxicity and treatment discontinuation rates have been documented [7,8]. Guidelines do not recommend age- or frailty-based initial dose adjustments, leaving oncologists to individualize treatment without prospective evidence.

KW - CDK4/6 inhibitors

KW - Dose reduction

KW - Geriatric oncology

KW - Metastatic breast cancer

KW - Multinational survey

KW - Prescribing practices

KW - 3122 Cancers

U2 - 10.1016/j.jgo.2026.103068

DO - 10.1016/j.jgo.2026.103068

M3 - Letter

C2 - 42447829

SN - 1879-4068

VL - 17

JO - Journal of geriatric oncology

JF - Journal of geriatric oncology

IS - 7

M1 - 103068

ER -